New hope for liver cancer patients: experimental drug HH-009 enters trial
NCT ID NCT07547553
First seen Apr 29, 2026 · Last updated May 23, 2026 · Updated 5 times
Summary
This study tests an experimental drug called HH-009 in about 30 people with advanced liver cancer that has gotten worse after other treatments. Participants will receive one of two doses of HH-009 every three weeks. The goal is to see if the drug can slow cancer growth and how safe it is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Tumor Hospital of Guangxi Medical University
Nanning, Guangxi, China
-
Anhui Provincial Hospital
Hefei, Anhui, China
-
Capital Medical University Affiliated Beijing Ditan Hospital
Beijing, Beijing Municipality, China
-
Guangxi Zhuang Autonomous Region People's Hospital
Nanning, Guangxi, China
-
Harbin Medical University Affiliated Cancer Hospital
Harbin, Heilongjiang, China
-
Henan Provincial Cancer Hospital
Zhengzhou, Henan, China
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
-
Jilin University First Hospital
Changchun, Jilin, China
-
Liaoning Cancer Hospital
Shenyang, Liaoning, China
-
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
-
NanFang Hospital of Southern Medical University
Guangzhou, Guangdong, China
-
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, China
-
Shanghai Gaobo Tumor Hospital
Shanghai, Shanghai Municipality, China
-
Shao Yi Fu Hospital, Affiliated to the School of Medicine of Zhejiang University
Hangzhou, Zhejiang, China
-
The Fifth Medical Center of the PLA General Hospital
Beijing, Beijing Municipality, China
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
-
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, China
-
The First Affiliated Hospital of Henan Medical University
Zhengzhou, Henan, China
-
Tianjin Medical University Cancer Hospital
Tianjin, Tianjin Municipality, China
-
Wells Prince Hospital of The Chinese University of Hong Kong
Hong Kong, Hong Kong, China
-
Zhongshan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.